Vectura Share Discussion Threads

[popper joe] 03/12/2019 13:21

I fail to see how buying-back the shares is supposed to be a positive for shareholders. I understand that there will be fewer shares in circulation as a consequence and so each share is worth a fraction more of the company. But the company then has £10m less in the bank and so is worth £10m less. So we end up owning a fraction more of a company that is worth slightly less.

[rogerrail] 03/12/2019 11:35

I still dont understand why VEC opted for a plan consisting of a special dividend, share consolidation and protracted share buyback instead of a straight forward tender offer. Makes me suspect they were badly advised by people who had something to gain ie inflated fees.

[alexchry] 03/12/2019 08:19

No doubt you are right, polaris, but it just feels like it will be forever!

[polaris] 03/12/2019 08:16

First month of buyback complete - just under £2 M committed for a little under 2.27 M shares at an average price of 85.86 p. HBM can't sell forever. The time is approaching where the selling pressure will finally dry up.

[best1467] 03/12/2019 07:29

Good news is exactly what’s needed and it’s been in extremely short supply for some considerable time forget HBM this is the sole reason we have performed so miserably for so long.

[frazboy] 02/12/2019 22:32

So, if you plot HBM percentage (which automatically accommodates the consolidation) against date for the last 5 holding RNSs, and if you use a best fit line extrapolated forwards, the data indicate that HBM will have sold out, at or around late May/early June next year.

And, at the present rate, JP Morgan, will complete phase I of the buyback at the expected date, which was published as 30th April.

So, I'm expecting the share price to remain under pressure throughout the buyback. It will need good news to see significant upward price action during this time.

Only a problem/issue if you're a short term trader though, I guess!?

[dp1umb] 02/12/2019 21:51

The flip side it does benefit us in the long run if Vectura are buying back the shares at a lower level.

[insideryou] 02/12/2019 20:12

It will be sods law that I sell out the next time it hits 90 and it bursts through the stale trading range

[best1467] 01/12/2019 15:51

Let’s hope 2020 is the year of delivery it’s about time

[base7] 29/11/2019 18:36

HBM continuing to sell ,almost certainly .Perhaps 2020 will be the year of the recovery & next Dec we will be over 150p ?

[phillkay] 29/11/2019 16:27

Why are there so many small sells, is this insti running down?

[phillkay] 29/11/2019 15:32

Recovery target I reckon soon.

[fhmktg] 28/11/2019 11:54

Steady cash flow from the overall relationship with Novartis.Huge potential market in China 'fourth highest cause of death'China has a massive problem with adult smoking as well as the well publicised urban pollution.

[best1467] 28/11/2019 11:46

It's certainly a positive but expected

[dp1umb] 28/11/2019 10:43

How significant is the news from China?

[richman777114] 27/11/2019 12:55

thanks polaris

[alexchry] 27/11/2019 09:18

A well-flagged announcement that tells us nothing new so not surprising there is little share price reaction for either company. We need to get some unexpected good news to get the share price moving, GSK dropping their appeal would be good start!

[polaris] 27/11/2019 07:48

Hikma has submitted the CRL to FDA for VR315 (generic Advair). About time but positive news none the less.

[polaris] 23/11/2019 12:48

If you look at the damages awarded and place them into fiscal years then VEC would have reported significantly higher revenues for all years from 2016 onwards. GSK action has materially influenced VEC share price in a negative way by refusing to re-license the patent family and continuing to sell the products involved under infringement. Those sales cannot be taken back...GSK still has $3 Bn in revenues whatever the outcome here.

If there is any truth in the generic Ellipta development meaning GSK are 'going after' VEC then i cannot see this ending well for the large pharma, especially in the US. SKP were screwed over by GSK with Paxil CR and i think GSK were just following usual modus operandi in dealings with VEC - beat up the smaller company approach.

I hope that, finally, GSK will get the massive slap they deserve...in court. This would be throwing out the appeal, granting it is frivolous, and imposing further damages and costs to VEC for wasting the court's time. I can but dream! ;-)

edit
Maybe VEC can ask for suspension of sales while the appeal is heard...now that would be holding GSK over the barrel!

[base7] 23/11/2019 12:25

Apart from the financial loss of royalty revenue ,the Discontination Of royalty payments coincided with the weakness & stagnation in our share price as we were perceived to be a weak company -resulting in substantial reduction in our value -apart from cash flow loss